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Evidence suggests that the C-terminal truncation of -sy-
nuclein is equally important as aggregation of -synuclein in
Parkinson disease (PD). Our previous results showed that
an endopeptidase, matrix metalloproteinase-3 (MMP3), was
induced and activated in dopaminergic (DA) cells upon stress
conditions. Here, we report that MMP3 cleaved -synuclein in
vitro and in vivo and that-synuclein andMMP3were co-local-
ized in Lewy bodies (LB) in the postmortem brains of PD
patients. Incubation of-synuclein with the catalytic domain of
MMP3 (cMMP3) resulted in generation of several peptides, and
the peptide profiles of WT -synuclein (WTsyn) and A53T
mutant (A53Tsyn) were different. Combined analysis using
mass spectrometry andN-terminal determination revealed that
MMP3 generated C-terminally truncated peptides of amino
acids 1–78, 1–91, and 1–93 and that A53Tsyn produced signif-
icantly higher quantities of these peptides. Similar sizes of pep-
tides were detected in N27 DA cells under oxidative stress and
RNA interference to knock down MMP3-attenuated peptide
generation. Co-overexpression of cMMP3with eitherWTsyn or
A53Tsyn led to a reduction in Triton X-100-insoluble aggre-
gates and an increase in protofibril-like small aggregates. In
addition, overexpression of the 1–93-amino acid peptide in the
substantia nigra led to DA neuronal loss without LB-like aggre-
gate formation. The results strongly indicate that MMP3 diges-
tion of -synuclein in DA neurons plays a pivotal role in the
progression of PD throughmodulation of -synuclein in aggre-
gation, LB formation, and neurotoxicity.
The epidemiological as well as animal studies suggest that
environmental factors, genetic predispositions, and the inter-
play between the two factors are implicated in the PD3 patho-
genesis (1), although the underlying molecular mechanisms
remain largely unknown. -Synuclein is a major component of
Lewy bodies (LB), the pathological hallmark of Parkinson dis-
ease (2). As expression of three mutant forms of -synuclein,
A53T, A30P, and E46K, in the brain (3–5) and increased copy
number by duplication or triplication of the wild-type -sy-
nuclein gene (6–8) have been reported in the early onset famil-
ial cases of PD, the pathophysiological role of these mutants of
-synuclein has been a target of extensive investigations in PD
research. The ability of -synuclein to aggregate and form
fibrillar deposits has been shown to play a central role in its
pathology. The facts that the presence of C-terminally trun-
cated-synuclein in LB of sporadic PD andLBdementia (9, 10),
the existence of various lengths of the truncated forms of -sy-
nuclein in brain (10, 11), and the formation of C-terminally
truncated -synuclein in A53T transgenic mice that show
motor symptoms (12) implicate the probable involvement of
endopeptidases in cleaving -synuclein in brains. In addition,
about 15% of -synuclein in LB are truncated forms, and
incomplete degradation of -synuclein produced highly amy-
loidogenic fragments (9, 13). Recent reports showed thatmatrix
metalloproteinases were able to cleave-synuclein, andMMP3
was the most efficient enzyme among them in cleaving -sy-
nuclein into several fragments (14). Several other proteinases
that include calpain, neurosin, and proteasome 20 S are known
to cleave -synuclein in DA neurons and are localized in or
around LB where -synuclein is localized (10, 15–18). How-
ever, the role of cleaved peptides is still obscure.
Increasing lines of evidence have linked matrix metallopro-
teinases to the pathogenesis of neurodegenerative diseases such
as Alzheimer and Parkinson disease (19–22). Our previous
studies demonstrated that MMP3 plays a crucial role in degen-
eration of dopaminergic neurons in substantia nigra (22, 23).
We have also demonstrated recently that the active MMP3
accumulated in the cytoplasm of DA cells under various stress
conditions was responsible for DJ-1 degradation and abolished
antioxidant property of DJ-1 (24).
We investigated the following: (i) whether active MMP3
cleaves -synuclein in DA neuronal cells under stress condi-
tions; (ii) whether MMP3-mediated cleavage of WT and
mutant -synucleins yields different sizes and quantities of
peptides; (iii) whether differentially cleaved peptides have their
specific pathophysiological properties, and (iv)whether cleaved
peptides play significant roles in DA neuronal degeneration in
vivo. Here, we present evidence that MMP3-mediated -sy-
nuclein cleavage plays a pivotal role in the pathogenesis of PD.
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EXPERIMENTAL PROCEDURES
Materials—Recombinant -synuclein peptides (WTsyn,
A53Tsyn, and A30Psyn) were purchased from rPeptide, LLC
(Bogart, GA). Fetal bovine serum (FBS) and cell culture
reagents were bought from Invitrogen. Nisobutyl-N-(4-me-
thoxyphenylsulfonyl)glycyl hydroxamic acid (NNGH) was pur-
chased from Biomol International (Plymouth Meeting, PA).
The recombinant catalytic domain of MMP3 protein was
obtained from Calbiochem. Goat polyclonal anti-MMP3
antibody and rabbit polyclonal -synuclein antibody were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
Monoclonal anti-FLAG antibody was obtained from Sigma.
Secondary antibodies were obtained from Jackson Immuno-
Research (West Grove, PA). NuPAGE Tricine-ready gels (10–
20% polyacrylamide), prestained SDS-PAGE standards (broad
range), MMP3 siRNA and control constructs, and Lipo-
fectamine 2000 were from Invitrogen. Primers were synthe-
sized at Invitrogen. The Flp-InTM T-RexTM system for tetracy-
cline-inducible cell line establishment was purchased from
Invitrogen. First strand DNA synthesis kit was purchased from
Roche Applied Science. PCR master mix was from Promega
(Madison, WI). All other chemicals were reagent grade and
were bought from Sigma or Merck.
Human Substantia Nigra Materials and Immuno-
histochemistry—Paraffin-embedded, formalin-fixed brain tis-
sues from nine PD samples and six normal controls were
obtained from the New York Brain Bank at Colombia Univer-
sity. History was obtained by retrospective chart analysis at the
time of autopsy or collected prospectively. Postmortem inter-
vals were less than 24 h in most cases (Table 1). Control cases
had no recognizable pathology in the brain, and PD cases had
diagnostic pathology (disappearance of DA neurons and Lewy
bodies) on hematoxylin and eosin-stained slides. Immunohis-
tochemistry was performed using MMP3 antibody that reacts
with the C-terminal hemopexin domain of the human MMP3
(Santa Cruz Biotechnology) at 1:50 dilution or -synuclein
antibody (Santa Cruz Biotechnology). Paraffin-embedded
human brain sections were incubated in citrate buffer at 95 °C
for 20 min for antigen retrieval. Staining was completed using
the tyramide signal amplification biotin system (PerkinElmer
Life Sciences). We used the Vectastain Elite ABC kit from Vec-
tor Laboratories (Burlingame, CA) at 1:200 followed by expo-
sure to tyramide solution according to the manufacturer’s
instructions. To develop color, diaminobenzidine (brown) was
used as the chromogen. Sections were lightly counterstained
with hematoxylin. For antibody blocking, MMP3 antibody was
pre-absorbed with a 5-fold high concentration of blocking pep-
tide (Santa Cruz Biotechnology) in 500 l of PBS at room tem-
perature for 2 h.
Digestion of Recombinant -Synucleins by MMP3 and Pro-
tein Gel Electrophoresis—500 ng of each recombinant -sy-
nuclein peptide was incubated with recombinant catalytic
domain of human MMP3 (cMMP3) at various concentrations
(250 ng/ml to 2 g/ml) in 30 l of PBS for various duration (5
min to 1 h). Reactions weremixed with loading buffer and were
subjected to SDS-PAGE using 10–20% Tricine gels. Protein
was detected by Coomassie Brilliant Blue staining.
Transient Transfection of -Synuclein Tagged with FLAG
(N-terminal) and Myc (C-terminal), MMP3 Knockdown by
siRNA, and Western Blot Analysis—Human -synuclein was
cloned into the p3FLAG-myc-CMVTM-23 expression vector
(Sigma) for N- and C-terminal tagging with FLAG and Myc,
respectively. Site-directed mutagenesis using PCR was used for
constructing A53T mutation. For transient overexpression of
tagged -synuclein, SN4741 cells or N27 cells were plated onto
6-well plates at 5 105 cells per well 1 day prior to transfection.
The next day, cell were transiently transfected with either
FLAG-WTsyn-myc or FLAG-A53Tsyn-myc. Briefly, 1 g of
plasmid DNA was mixed with 4 l of Lipofectamine 2000
(Invitrogen) in 100l ofOpti-MEMfor 20minprior to addition
in the culture. 4 h after incubation, culture mediumwas freshly
exchanged. Cells were treated with various toxic stimuli after
overnight incubation. For MMP3 inhibition, cells were treated
with NNGH (100 M) 30 min prior to each stimuli. Total pro-
tein lysates were prepared 24 h after toxic stimuli, and N- and
C-terminal fragmentations were determined by Western blot
analysis using anti-FLAG and anti-Myc antibodies, respec-
tively. To knock down MMP3 in N27 cells, three siRNA con-
structs were purchased from Invitrogen (Stealth RNAi) and
tested for knockdown efficiency. The sense and antisense oli-
gonucleotides were annealed following themanufacturer’s pro-
tocol to generate double-stranded siRNAs at the final concen-
tration of 20 M. N27 cells were grown to 80% confluency in
6-well culture plates and were subjected to co-transfection by
incubation with 8 l of 20 M siRNAs (final concentration 40
nM) and 1 g of -synuclein plasmid in 100 l of Opti-MEM
containing 10l of Lipofectamine 2000. After 6 h of incubation,
the culture medium was freshly changed, and cells were main-
tained for additional 30 h before analysis. Stealth RNAi with a
similar GC content was used for negative control.
Co-expression of-Synuclein andCatalytically ActiveMMP3
in COS Cells Using Adenovirus—Human WTsyn, A53Tsyn,
MMP3 catalytic domain (amino acid 100–273, and inactive
mutated one (E219A) were cloned into the pENTR/D TOPO
vector (Invitrogen) by PCR and then subcloned into the pAd/
CMV/V5-DEST, adenovirus-mediated expression vector by
site-specific recombination using clonase (Invitrogen). These
viral constructs were transfected into HEK293 cells to obtain
recombinant viruses, followed by virus amplification and puri-
fication based on the manufacturer’s protocol. Viral titers were
determined by methods previously described (25). Because the
N-terminal prodomain, which is responsible for inhibition of
catalytic activity ofMMP3, was removed, overexpression of the
catalytic domain produced an enzymatically active MMP3.
Establishment of Tetracycline-inducible -Synuclein Cell
Lines—Human -synuclein constructs (full-length, 1–78,
1–91, and 1–93 amino acids of WTsyn and A53Tsyn) were
cloned into the pcDNA5/FRT/TO©TOPOTAvector contain-
ing a tetracycline-inducible promoter (Invitrogen). To establish
the tetracycline-inducible expression system, the Flp-InTM
T-RExTM 293 cell line (Invitrogen), which contains a single Flp
recombination target site and tetracycline repressor in their
genome, was used. Integration of an expression vector contain-
ing each -synuclein construct into the genome via Flp recom-
binase-mediatedDNA recombination at the Flp recombination
-Synuclein Cleavage byMMP3
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target site produced isogenic cell lines. Tetracycline (5 g/ml)-
regulatable expression of the relevant construct was tested by
Western blot analysis using anti-V5 antibody.
Establishment of Adeno-associated Viral (AAV) Constructs
and AAV Packaging—FLAG-tagged full-length A53T or
A53T1–93 peptide were subcloned into the CMV-IRES-
hrGFP/AAV2 (A53Tsyn/AAV or A53T1–93/AAV). Either
empty vector, A53Tsyn/AAV, or A53T1–93/AAV was co-
transfected with pHelper and pAAV-RC to HEK293 cells using
a standard calciumphosphatemethod.After 72 h, the cellswere
harvested, and crude rAAV vector solutions were obtained by
repeated freeze/thaw cycles. The cleared crude lysate was then
applied on a heparin-agarose column (Sigma). After all the
lysate went through the column, the matrix was washed twice
with 25 ml of PBS (pH 7.4, 0.1 M NaCl). The virus was then
eluted with 15 ml of PBS (pH 7.4, 0.4 M NaCl). The eluent was
concentrated to about 1 ml with a Millipore Centriplus YM-30
centrifugal filter by centrifugation at 4000 relative centrifugal
force for 15–40min. To adjust theNaCl concentration to phys-
iological levels, the filter device was refilled with PBS, pH 7.4,
and the virus was concentrated to 250–300 l again. After
removal of the virus-containing solution, the membrane of the
filter device was washed three times with 100l of PBS, pH 7.4,
which was added to the main part of the recombinant AAV2.
The fractions containing high titer rAAV vectors were col-
lected andused for injection into animals. The number of rAAV
genome copies was semiquantified by PCR within the CMV
promoter region using primers 5-GACGTCAATAATGACG-
TATG-3 and 5-GGTAATAGCGATGACTAATACG-3.
Overexpression of Full-length A53T or A53T1–93 in the Rat
SN by Stereotaxic Delivery of AAV Viral Particles—The exper-
iments were carried out on rat, in accordance with the Guide
for theCare andUse of LaboratoryAnimals (National Institutes
of Health). All procedures were approved by the local Animal
Care and Use Committee. Female Sprague-Dawley (SD) rats
(Charles River; 8 weeks old at the time of the beginning of AAV
expression, 2–3 per cage) were maintained in a temperature/
humidity-controlled environment under a 12-h light/dark cycle
with free access to food and water. All rats were allocated into
two groups, full-length A53T/AAV and A53T1–93/AAV. Rats
were deeply anesthetized (30 mg/kg ketamine and xylazine
mixture, intraperitoneally) and placed in a rat stereotactic
apparatus, a site in the right SN (coordinates: anteroposterior,
5.3mm;mediolateral,2.0mm; dorsoventral,5.8mm)was
selected to inject full-length A53T/AAV (n 8) or A53T1–93/
AAV (n 8). For the negative control, AAV containing empty
vector was injected into the contralateral side (coordinates:
anteroposterior, 5.3 mm; mediolateral, 2.0 mm; dorsoven-
tral, 5.8 mm). A total of 1  1011 genome copy/ml rAAV
particles diluted in 2 l of ice-cold sterilized phosphate-buff-
ered saline (PBS) were used in every animal. 12 weeks later, the
animals were sacrificed.
Data Analysis and Statistics—Statistical analysis was carried
out with GraphPad Prism version 5 (GraphPad Software Inc.,
San Diego). Data are expressed as percentages of values
obtained in control conditions and are presented as means 
S.E. of at least four individual experiments. Statistical analyses
were performed using the Student’s t test or one-way analysis of
variance followed by Bonferroni’s multiple comparison test.
Values of p 0.05 were considered significant.
RESULTS
MMP3 Is Co-localized with-Synuclein in the LB in the SN of
PostmortemBrains of PD Patients—Two adjacent sections with
6-m thickness of the SN area of postmortem brains of PD
patients (Table 1) were stained with either MMP3 antibody or
-synuclein antibody. Although MMP3 was barely detected in
control brain samples, it was localized in LB with strong
staining in the intermediate zone where outer filaments start
(Fig. 1, A and B); although its localization pattern in LB var-
ied, it was mainly in the outer halo but was sometimes homo-
geneously distributed. Interestingly, MMP3 was not present
in all LB that are -synuclein-positive (Fig. 1A, lower panels).
About 57% of Lewy bodies were co-stained with MMP3.
MMP3 antibody preincubated with antigen-peptides failed
to detect MMP3 in the adjacent sections (Fig. 1C). MMP3
was also localized in the cytoplasm. Whether MMP3 in the
LB is catalytically active is unknown. MMP3 level was in-
creased in the postmortem brain tissue of PD patients com-
pared with control (supplemental Fig. 1).
Differential Cleavage of WT -Synuclein (WTsyn) and A53T
Mutant (A53Tsyn) by cMMP3 and Generation of C-terminally
Truncated Peptides—We first tested whether WTsyn was
digested by the recombinant catalytic domain of MMP3
(cMMP3). WTsyn (500 ng) was mixed with various concentra-
tions of cMMP3 (250 ng/ml to 2 g/ml) for 60 min. Two dis-
tinguishable peptides (peptide-a and -b on gel) and several
other peptides with highermolecular weight were generated by
the lowest concentration of cMMP3 (250 ng/ml), and more
peptides of lower molecular weight were produced by higher
concentrations of cMMP3 (Fig. 2A). Preincubation of cMMP3
(2 g/ml) with NNGH (20 or 100 M), an MMP3 inhibitor,
prevented -synuclein digestion. MMP9 did not cleave -sy-
nuclein (Fig. 2A), suggesting cleavage of -synuclein was
MMP3-specific. Cleavage of -synuclein by cMMP3 over a
period of time in the same conditions showed that two peptides
(peptide-a and -b in Fig. 2B) were generated within 5 min, and
more peptides were produced at a later time (30min after incu-
TABLE 1
List of postmortem human brain tissues
Nine PD samples and six normal controls were obtained from the New York Brain
Bank atColombiaUniversity.Historywas obtained by retrospective chart analysis at
the time of autopsy or collected prospectively. Postmortem intervals were less than







PD T243 77/F 11:50 Parkinson disease, moderate
T227 76/F 6:44 Parkinson disease, severe
T155 83/F 11:27 Parkinson disease, moderate
T112 78/M 9:04 Parkinson disease, severe
T306 80/F 3:20 Parkinson disease
T177 84/F 3:30 Parkinson disease
T127 89/M 5:50 Parkinson disease
T72 81/M 2:30 Parkinson disease
T9 74/M 4:15 Parkinson disease
Control T198 82/M 3:50 Normal
T206 49/M 13:55 Normal
T230 87/M 5:10 Normal
T346 84/M 10:00 Normal
T52 80/M Not available Normal
T110 62/M Not available Normal
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bation), but the intensity of peptide-a and -b remained strong,
suggesting that peptide-a and -b were preferentially generated
by cMMP3 as reported by others (14). To find differential cleav-
ages of -synuclein mutants by cMMP3, two human mutant
recombinant -synuclein variants (A30Psyn and A53Tsyn) in
addition toWTsyn (1 g each) were incubated with cMMP3 (1
g/ml) for 1 h. Peptides generated from A53Tsyn by cMMP3
differed from those of WTsyn or A30Psyn, showing increased
intensity of peptide-a and -b and a new appearance of an addi-
tional low molecular weight band (peptide-c) (Fig. 2C). The
result suggests that conformational change caused by A53T
mutation modifies MMP3-mediated digestion property. We
also incubated-synucleinwith cMMP3, demonstrating differ-
ential fragment generation (supplemental Fig. 2). Fourier trans-
form-ion cyclotron resonance mass spectrometry in conjunc-
tion with N-terminal determination using Edman degradation
was used to identify the cleavage sites for peptide-a, -b, and -c in
-synuclein. The amino acid sequences of all three peptides
started with a first amino acid of noncleaved -synuclein, sug-
gesting cMMP3 digested these -synucleins from their C ter-
mini. The spectrometric pattern of peptides of A53Tsyn was
different from those of WTsyn or A30Psyn (Fig. 3A). Based on
the calculated masses and first amino acid of each peptide, the
cleavage site of each peptide was determined. Peptide band-a
consisted of two peptides, amino acids 1–93 and 1–91, and
peptide band-b consisted of two peptides, amino acid 1–78 and
1–77. Peptide band-c was a single peptide of amino acids 1–47
(Fig. 3B). Two peptides, 1–91 and 1–78, in A53Tsyn digestion
were distinguishable among others with their high intensity.
N-terminal Fragments of-SynucleinGenerated byMMP3 in
Stressed DA Cells—We sought to investigate whether MMP3-
elicited -synuclein fragmentation also occurs in DA cells after
stress. Our previous studies demonstrated that expression and
activity of MMP3 were increased in DA cells under stress con-
ditions (22), and intracellular activation of MMP3 resulted in
apoptosis of DA cells (23). We demonstrate here that the cata-
lytically active form of MMP3 was induced in N27 cells, a rat
DA cell line, after treatment with H2O2 and 6-hydroxydop-
amine (6-OHDA) (Fig. 4A). Proteasomal inhibition and the
presence of rotenone also led to MMP3 activation (data not
shown). Under these conditions, the generation of -synuclein
fragments was investigated using FLAG-WTsyn-myc (-sy-
nuclein tagged with FLAG for N terminus and with Myc for C
terminus) construct, because antibodies against theN terminus
we tested were not effective. When FLAG-WTsyn-myc-over-
expressedN27 cells were cultured in the presence of H2O2 (100
M) or 6-OHDA (50 M) for 24 h, tagged -synuclein was frag-
mented (Fig. 4B). Molecular sizes of fragmented N-terminal
peptides were equivalent to those obtained in in vitro cleavage
of -synuclein by cMMP3 (Fig. 4B). Anti-Myc antibody de-
tected only full-length-synuclein, suggesting that noC-termi-
nal peptides were generated (Fig. 4C). To test whether MMP3
was responsible for this fragmentation,MMP3was inhibited by
siRNA-mediated knockdown prior to H2O2 (100 M) treat-
ment. Transfection of siRNA targeting MMP3 significantly
reducedMMP3 in bothmRNA and protein levels (Fig. 4,D and
E). Knockdown of MMP3 using siRNA reduced H2O2-induced
fragmented peptide generation (Fig. 4B). The results demon-
strated that MMP3 cleavage of -synuclein did occur in DA
cells in stressful conditions.
Co-overexpression of ActiveMMP3 and -Synuclein Resulted
in Decreased Insoluble Aggregates and Increased Formation of
Protofibril-like Aggregates—To characterize intracellular path-
ogenic molecular species of -synuclein generated by MMP3
cleavage,we first tested co-overexpression of cMMP3and-sy-
nuclein into SN4741 cells by employing recombinant adenovi-
ral transduction. Unfortunately, adenoviral constructs were
highly toxic to SN4741 cells. As an alternative, COS cells that
are known to be relatively resistant to adenoviral transduction
were used (26). COS cells were co-transduced with adenovirus
expressing WTsyn or A53Tsyn combined with one carrying
cMMP3. Adenovirus expressing catalytically inactive mutant
MMP3 (mutMMP3) was used as a negative control. Size exclu-
sion filter assay was performed to characterize Triton X-100-
insoluble -synuclein aggregates at various time points (24, 48,
and 72 h) after transduction. The result showed that A53Tsyn
FIGURE1. ImmunostainingofMMP3and-synuclein inLewybodies in theSNofpostmortembrainsofPDpatients.A, representativephotomicrographs
of adjacent sections of the SN tissues immunostained with MMP3 (left column) or -synuclein (right column) show MMP3 staining in LB. B, representative
photomicrograph of neuromelanin-positive dopaminergic neuron in the SN. Arrowhead indicates neuromelanin granules. Arrow indicates Lewy body stained
with MMP3. Approximately 50 Lewy bodies stained with -synuclein were analyzed. 57% of them were co-stained with MMP3. C, disappearance of MMP3
staining in LB after antibody absorption with blocking peptide. MMP3 antibody specificity was evaluated by preincubation with specific blocking peptide for
30min.Right column,MMP3 immunostainingwithoutblocking; left column, immunostainingafter antibodypreincubationwithblockingpeptide; lower panels,
enlarged view of designated boxed areas a and b.
-Synuclein Cleavage byMMP3
APRIL 22, 2011•VOLUME 286•NUMBER 16 JOURNAL OF BIOLOGICAL CHEMISTRY 14171
formedmore insoluble aggregates thanWTsyn, and co-overex-
pression with cMMP3 resulted in reduced formation of insolu-
ble aggregates of -synucleins (both WT and A53T) (Fig. 5A).
Immunochemical staining of aggregates showed that overex-
pression of -synuclein in COS cells produced two distinct
types of aggregates, LB-like large perinuclear inclusions and
small punctated aggregates scattered throughout the cytoplasm
that are similar to those observed by others (27). The -sy-
nuclein immunohistochemistry of the aggregates in COS cells
co-overexpressing cMMP3 with WTsyn or A53Tsyn for 72 h
after adenoviral transduction showed the following: 1) co-over-
expression of full-length A53Tsyn and mutMMP3 resulted in
perinuclear inclusion formation; 2) cMMP3 cleavage led to
smaller A53Tsyn aggregates; 3)WTsyn did not form any visible
inclusions at this time point; and 4) co-overexpression with
cMMP3, however, produced small punctated aggregates in the
cytoplasm (Fig. 5B).
To further characterize each -synuclein fragment gener-
ated by MMP3 cleavage, tetracycline-inducible cell lines stably
expressing FLAG-WTsyn, FLAG-A53Tsyn, and their MMP3-
cleaved peptides (aa 1–78, 1–91, and 1–93 peptides of WTsyn
and A53Tsyn) were established. Tetracycline inducibility was
tested by measuring both mRNA and protein levels. Cells
treated with 5 g/ml tetracycline overnight reached maximum
expressions. Interestingly, protein expression of aa 1–91 pep-
tides of WTsyn and A53Tsyn (WT1–93 and A53T1–93,
respectively) was less than others, although their mRNA levels
were similar to others (supplemental Fig. 3). Immunocyto-
chemistry using anti-FLAG antibody at 72 h after tetracycline
FIGURE 2. Cleavage of WT (WTsyn) and mutant (A53Tsyn) recombinant
-synucleins by catalytic domain of MMP3 (cMMP3). A, cMMP3 dose-de-
pendent digestion of WTsyn. WTsyn (500 ng) was incubated with various
concentrations of cMMP3 (250 ng/ml and 1 and 2 g/ml) at 37 °C for 1 h.
NNGH (20 and 100 M) was preincubated with cMMP3 (1 g/ml) for 30 min
prior to -synuclein. WT recombinant -synuclein was also incubated with
cMMP9 (1g/ml). Cleaved peptideswere detected by SDS-PAGE followed by
Coomassie Blue staining. a and b indicate peptide bands generated at the
lowest cMMP3 concentration (250 ng/ml). B, time course cleavage of WTsyn
by cMMP3. Recombinant WTsyn (500 ng) was incubated with cMMP3 (1
g/ml) at 37 °C for various durations (5, 15, and 30min and 1 h), and cleaved
peptides were detected by SDS-PAGE followed by Coomassie Blue staining.
Note that peptide bands a and b (arrows) were most efficiently generated
within 5 min. C, differential cleavage of A53Tsyn from WTsyn. cMMP3 (1
g/ml) was added to recombinant WTsyn, A30Psyn, or A53Tsyn (500 ng
each), and after 1 h of incubation, generated peptideswere detected by SDS-
PAGE followed by Coomassie Blue staining. a and b, bands most intensely
stained in A53Tsyn; c, band exclusively generated in A53Tsyn.
FIGURE 3.Mass spectrometric analysis of peptides generated from both
WT andmutants form of-synuclein by cMMP3 cleavage. A, after 30 min
of incubation with cMMP3 (1 g/ml), peptides from WTsyn, A30Psyn, and
A53Tsyn (1 g each) were analyzed by Fourier transform-ion cyclotron reso-
nance mass spectrometry. Blue ovals represent two strong peaks generated
exclusively in A53Tsyn. B, amino acid sequences and intensity determined
accordingly with deconvolutedm/z values and N-terminal amino acids. Note
that band a consists of two peptides (1–93 and 1–91 aa), and band b also
consists of two (1–79 and 1–78 aa). Band c is one peptide of 1–47 aa, which is
exclusively generated from A53T.
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treatment showed that, whereas full-length A53Tsyn formed
inclusions near the nucleus, WTsyn1–93 and A53T1–93
yielded increased small aggregates throughout the cytoplasm
(Fig. 5C). Full-length WTsyn and aa 1–78 of WTsyn and
A53Tsyn showed diffuse cytoplasmic stainingwithout aggrega-
tion (Fig. 5C).
MMP3-cleaved -Synuclein Fragments Localized into the
Mitochondrial Matrix and A53T1–93 Decreased Mitochon-
drial O2 Consumption—An increasing body of evidence dem-
onstrated that the interaction between -synuclein and
mitochondria is an important part in DA neurodegeneration
(28–31). Our aim was to test whether MMP3-cleaved -sy-
nuclein peptides are differentially localized in themitochondria
and whether they differentially affect mitochondrial functions.
All fragments were localized into the mitochondria when -sy-
nuclein species were induced with tetracycline (5 g/m) for 5
days. However, only WT1–93 and A53T1–93 reduced mito-
chondrial O2 consumption, and A53T1–93 was more effective
than WT1–93 in reducing O2 consumption (Fig. 6A). Here,
YFP-expressing cells similarly treated were used as control.
Growing cells in the galactose media, which forces cells to uti-
lize mitochondria for ATP generation instead of glycolysis, led
to the most significant cell death in cells expressing A53T1–93
(Fig. 6B).
Proteinase K (PK) protection assay was employed to deter-
mine submitochondrial localization of both full-length and
1–93-aa fragments. Optimal conditions that preserved the
integrity of the mitochondrial inner membrane were deter-
mined in mitochondrial fractions of cells overexpressing full
A53T after incubation with various PK concentrations. Pro-
teins in all compartments were almost completely degraded at
50 and 100g/ml of PK. At a concentration of 5g/ml, voltage-
dependent anion channel (integral protein in outermembrane)
was partially digested; cytochrome c (inter-membrane space)
was almost completely degraded, and Cox I (inner mem-
brane) was slightly digested. At the same concentration, -sy-
nuclein was protected from PK digestion (Fig. 6C). This
suggests that PK is not able to digest matrix protein at this
concentration. Thus, we used a 5g/ml concentration of PK to
test other -synuclein species. Because the voltage-dependent
anion channel was not efficiently digested by PK, we used
Tom20 as outer membrane marker. Although PK completely
degraded Tom20, Hsp60 (matrix protein) was protected from
PK digestion. At this concentration, full-length -synucleins
(WT and A53T) were not degraded and 1–93-aa fragments
were slightly digested, suggesting that both forms are mainly
localized into thematrix (Fig. 6D). Using anti-Akt antibody and
anti-Tim-23 antibody for cytosolic and mitochondrial frac-
tions, respectively, efficiency of mitochondrial fractionation
was verified.
A53T1–93-mediated SNDA Neurodegeneration in Vivo—As
described above, MMP3-cleaved -synuclein, especially
A53T1–93 resulted in cytotoxicity. This result is consistent
with others demonstrating that application of MMP3-digested
-synuclein elicits increased cytotoxicity (14). To investigate
toxicity of A53T1–93 in dopaminergic neurons in the nigros-
triatal pathway, we overexpressed both full-length and
A53T1–93 taggedwith FLAG in the rat SN by stereotaxic deliv-
ery of rAAV carrying each construct into the SN. AAV harbor-
ing empty vectorwas injected at the same coordinate as control.
FIGURE 4. Stress-mediatedMMP3 activation and generation of-synuclein N-terminal fragments in dopaminergic cells. A,N27 cells were treatedwith
either 6-OHDA (50 M) or H2O2 (100 M) for 24 h. Both pro- and active MMP3 in total lysates were detected by Western blot analysis. B and C, N27 cells were
transiently transfected with FLAG-WTsyn-myc, and then 48 h later, cells were treated with 6-OHDA (50 M) or H2O2 (100 M) for 24 h. B, various N-terminal
fragments were generated, and they were detected by anti-FLAG antibody. C, C-terminal fragment was determined using anti-Myc antibody. D and E,
siRNA-mediatedMMP3knockdownefficiencywas tested inN27 cells. N27 cellswere transiently transfectedwith either control siRNAor siRNA targetingMMP3
(MMP3 siRNA) for 24 h and then cells were treated with H2O2 (100 M) for 24 h. D, MMP3 mRNA level was determined by RT-PCR. E, MMP3 protein level was
determined by Western blot analysis. Three independent experiments were performed, and representative photomicrographs are shown.
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AAV transduction efficiencywasmonitored byGFP, whichwas
bicistronically expressed. Four weeks after AAV injection,
about 75%of tyrosine hydroxylase (TH)-positiveDA cells in the
SN expressed GFP (supplemental Fig. 4). DA neuronal loss and
-synuclein aggregationwere examinedwith anti-TH and anti-
FLAG antibody, respectively, at 12 weeks post-AAV injection.
Both full-length A53T and A53T1–93 caused degeneration of
DA neurons in the SN (Fig. 7A, upper and lower panels). About
30% of TH-positive DA neuronal loss was observed in the SN
overexpressing A53T1–93 compared with control (Fig. 7B).
Nissl staining also showed a similar decrease in A53T1–93 (Fig.
7C). -Synuclein staining using anti-FLAG antibody showed
that LB-like inclusions were only formed by full-length A53T
but not by A53T1–93 (Fig. 7D).
DISCUSSION
Intracellular existence of matrix metalloproteinase and its
activation under various conditions have been reported (23, 32,
33). In the previous study, we demonstrated thatMMP3 is acti-
vated in DA cells treated with 1-methyl-4-phenylpyridinium,
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated
DA neuronal degeneration in the mouse SN was largely atten-
uated in Mmp3 null mice (22). We have also shown that
intracellularly activatedMMP3 participated in apoptosis of DA
cells in the presence of toxic stimuli (23). More recently, we
demonstrated that activeMMP3digestsDJ-1, abolishes its anti-
oxidant function, and eventually leads to dopaminergic neuro-
nal degeneration (24). These data suggest thatMMP3 activity is
not limited outside cells, but intracellular MMP3 is active as an
endopeptidase and interacts with available substrates in cells.
We also show herein MMP3 immunoreactivity in cytoplasmic
inclusions, LB in nigral DA neurons of postmortem brain tissue
from PD patients (Fig. 1). A majority of these LB where MMP3
is localized also contains-synuclein. This observation led us to
believe that intracellular interaction of activeMMP3with-sy-
nuclein, probably cleaving -synuclein, is possible. Serine pro-
tease neurosin also can cleave -synuclein and co-localize with
LB (16, 17). A number of studies suggests that inclusion body
formation is a part of cellular protection mechanism by reduc-
ing diffuse distribution of toxic molecules (34, 35). Stress-in-
duced intracellular MMP3 activity might be harmful to DA
neurons, and thus cells actively limit its spread by trapping it
within the inclusion bodies. Another explanation is thatMMP3
might be passively localized with its substrates to LB. Whether
MMP3 in LB is enzymatically active or it exists as proform
remains to be elucidated.
Consistent with other studies (14, 36), we also observed here
that MMP3 cleaved -synuclein in vitro, generating several
N-terminal fragments (Fig. 2). Other matrix metalloprotei-
nases, including MMP-1,-2, and -9, were analyzed in the post-
mortem brain tissue fromPDpatients (20). They demonstrated
that MMP9 is primarily found in neurons in the SN. In our
study, we tested whetherMMP9 also cleaves-synuclein, but it
did not digest -synuclein, suggesting the specificity of MMP3
on -synuclein cleavage (Fig. 2). Interestingly, mass spectrom-
etry combined with N-terminal determination using Edman
degradation identified that MMP3 generated 1–93, 1–91, and
1–78 peptides of both WTsyn and A53Tsyn, and A53Tsyn
yielded more of these peptides (Fig. 3). The result may imply
that structural alterations resulting from A53T mutation
changes its interaction with MMP3.
-Synuclein peptides that have equivalent size to ones gen-
erated by MMP3 in vitro was detected in DA cells treated with
FIGURE 5. Decreased insoluble -synuclein aggregates and increased
protofibril-like small aggregate formation by MMP3. A, WTsyn and
A53Tsyn were co-overexpressed either with cMMP3 or mutMMP3 (catalyti-
cally inactive construct) in COS cells for 24, 48, and 72 h. Triton X-100-insolu-
ble aggregates were determined by filter trap assay. -Synuclein was visual-
ized using anti--synuclein antibody. B, representative photomicrograph of
-synuclein immunostaining in COS cells co-overexpressing either WTsyn or
A53Tsynwith cMMP3 ormutMMP3 for 72 h.-Synucleinwas visualized using
anti--synuclein antibody. Arrows indicate perinuclear inclusions; arrow-
heads indicate protofibril-like small punctate aggregates. Right panels show
magnified images of a single cell. C, representative photomicrograph of-sy-
nuclein immunostaining in tetracycline-inducible 293 cells expressing full-
length WTsyn, A53Tsyn, and 1–93- and 1–78-amino acid peptides (WTsyn,
A53Tsyn, WT1–93, A53T1–93, and A53T1–78, respectively). After 72 h of incu-
bation with tetracycline, -synuclein was visualized using anti--synuclein
antibody. Arrows indicate perinuclear inclusions; arrowheads indicate proto-
fibril-like small punctate aggregates.
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various toxic stimuli such as H2O2, rotenone, and 6-OHDA.
Increased expression and intracellular activation ofMMP3was
commonly observed under these stress conditions, and MMP3
inhibitions using siRNA resulted in decreased cleavage (Fig. 4).
It has been demonstrated that C-terminally truncated peptide
generation occurs spontaneously and preferentially in A53T
transgenicmice (12). The size of those fragments range from 10
to 12 kDa and are correlated with neuropathological changes.
Smaller N-terminal fragments observed in our conditions may
result from MMP3 activation caused by toxic stimuli. Various
FIGURE 6. Localization of -synucleins into the mitochondrial matrix and significant decrease in mitochondrial O2 consumption and survival by
A53T1–93. Tetracycline-inducible 293 cells expressing various -synuclein constructs, including full-length WT and A53T, 1–93-amino acid WT, and A53T
(WTsyn, A53Tsyn, WT1–93, and A53T1–93, respectively), were incubated with tetracycline for 5 days. Tetracycline-inducible 293 cells overexpressing YFP were
used as a control. A,mitochondrial O2 consumption was measured. n 5. B, cell survival was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay after culture in galactose media for 1 week. n 5. C,mitochondrial fractions of cells overexpressing A53Tsyn were treated with
various concentrations of proteinase K (PK) (0–100 g/ml). Degradation of submitochondrial marker proteins and -synuclein were detected by specific
antibodies: Cyto C, cytochrome c (intermembranous space); -syn, anti-FLAG antibody; VDAC (voltage-dependent anion channel) (outer membrane); Cox1
(innermembrane).D,after incubationofmitochondrial fractionswith5g/mlPK for 30, degradationof submitochondrialmarkerproteins and-synucleinwas
detected by anti-Hsp60 antibody formatrix protein, anti-Tom20 antibody for outermembrane protei, and anti-FLAG antibody for-synuclein. Data are shown
as the mean S.D. Statistical analysis was performed using the Student t test. *, p 0.05 versus YFP; **, p 0.01 versus YFP.
FIGURE 7. Dopaminergic neurodegeneration in the substantia nigra induced by A53T1–93 -synuclein. Either full-length A53Tsyn or A53T1–93 was
overexpressed in the rat SN for 12weeks. THand-synucleinwere visualizedby immunostaining.A, representative TH immunostaining in the SN (upper panels,
full-length A53Tsyn; lower panels, A53T1–93; right, contralateral SN; left, ipsilateral SN). B, TH-positive DA neurons were stereologically counted, n  8.
C, Nissl-positive neurons were stereologically counted, n 8. Statistical analysis was performed using one-way analysis of variance followed by Bonferroni’s
multiple comparison test. *, p 0.01.D,A53T1–93 andA53Tsynwere visualized using anti-FLAG antibody in the SN. Although diffuse cytoplasmic distribution
was observed in A53T1–93, LB-like aggregate was detected in dopaminergic neurons overexpressing full-length A53T.
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protease-induced smaller peptide generations have been
reported (15, 37). The results suggest that under stress condi-
tions using toxic stimuli, MMP3-mediated proteolytic cleavage
of -synuclein may play a role in pathogenesis of PD.
MMP3 cleavage led to the change in aggregation property of
-synuclein. Although overexpression of full-length WTsyn in
COS cells for 72 h did not form detectible inclusions, A53Tsyn
resulted in perinuclear inclusion formations (Fig. 5B). Co-ex-
pressed with catalytically activeMMP3 (cMMP3), bothWTsyn
and A53Tsyn preferentially formed diffuse punctated staining
throughout the cytoplasmwithout large inclusions and showed
a mild increase in toxicity. It has been shown that overexpres-
sion of WTsyn in COS cells results in two distinct types of
aggregates, punctated small aggregates and large perinuclear
inclusion bodies. Biochemical analysis defined small aggregates
as the cellular equivalents of the protofibrils (27). It suggests
that small punctated cytoplasmic staining induced by co-over-
expression with cMMP3 can be the protofibril-like aggregates.
However, large juxtanuclear inclusions were exclusively ob-
served in COS cells overexpressing A53Tsyn but notWTsyn in
this study. This discrepancy might result from different -sy-
nuclein expression levels and incubation times. Similar to what
we observed in COS cells co-expressing A53Tsyn and cMMP3,
tetracycline-inducible 293 cells expressing A53T1–93 demon-
strated increased small punctated aggregates over time (Fig.
5C). Consistent with our data, electronmicroscopic analysis on
MMP3-digested-synuclein in vitro showed spherical granular
aggregate formations, and they were more toxic to cells than
undigested ones, suggesting protofibril intermediate formation
(14). Although devoid of two amino acids from the non-amy-
loid  component (non-A component of Alzheimer disease
amyloid, amino acid 61–95), A53T1–93 generated small proto-
fibril-like aggregates. In fact, it has been shown that the 12-
amino acid stretch (71VTGVTAVAQKTV82) in the middle of
the hydrophobic non-A component of Alzheimer disease
amyloid region of human -synuclein is necessary and suffi-
cient for its fibrillation (38). As expected, the 1–78-aa fragment
did not form any detectible aggregates. As shown in supple-
mental Fig. 1, tetracycline-inducible 293 cells harboring
WT1–91 andA53T1–91 showed less protein levels than others,
although its mRNA level is similar to others, implying protein
instability. This was also observed in SN4741 cells transiently
transfected with this construct. Molecular mechanism under-
lying this phenomenon might need further investigation.
It has been shown that mitochondrial complex I inhibition
and oxidative stress can promote -synuclein aggregation and
increase toxicity (26, 39). A53T transgenic mice reveal its asso-
ciation withmitochondria and that catalytic activity of Cox-I in
spinal cord is significantly reduced. Subsets of mitochondria
contain -synuclein and become dysmorphic. Another inter-
esting mitochondrial pathology observed is mitochondrial
DNA damage as seen by TUNEL assay (30). In this study, mito-
chondrial localization was not affected by MMP3-mediated
-synuclein cleavage (Fig. 6D). Mitochondrial O2 consump-
tion, however, was decreased by the 1–93-aa fragment.
A53T1–93 caused the most significant decrease in mitochon-
drial O2 consumption (Fig. 6A). Although it did not induce
direct cell death under high glucose culture conditions,
A53T1–93 led to significant cell death in culture medium con-
taining galactose in which cells are forced to utilize mitochon-
dria for ATP generation (Fig. 6B). A recent study identified the
N-terminal 32 amino acids of human -synuclein as a cryptic
mitochondrial targeting sequence, and -synuclein accumula-
tion resulted in reduced complex I activity (40). This suggests
that N-terminal fragments generated byMMP3 cleavage would
translocate into mitochondria. Mitochondrial functional
changes caused by each fragment, however, might be deter-
mined by its sequence and aggregation pattern.
Finally, we demonstrated that overexpression of A53T1–93
in the rat SNDA neurons led to neurodegeneration (Fig. 7).
Interestingly, although only full-length A53Tsyn was able to
form LB-like inclusions in the cytoplasm, both full-length and
A53T1–93 overexpression resulted in DA neuronal degenera-
tion. AAV2 was employed for neuron-specific delivery of full-
length A53Tsyn or A53T1–93 constructs. Increasing reports
have shown that AAV2-mediated gene transfer provides an
effective means of achieving long term expression of target
genes in nondividing cells such as neurons (41, 42). As shown in
supplemental Fig. 2, more than 70% of TH-positive neurons
were GFP-positive 4 weeks after AAV injection into the SN,
indicating efficient expression in DA neurons. It has been dem-
onstrated that AAV-mediated -synuclein delivery into the SN
resulted in DA neuronal degeneration in both rat and mouse
PD models (43, 44). Transgenic mice overexpressing amino
acid residues 1–130 of human -synuclein developed selective
dopaminergic neuronal loss in the substantia nigra pars com-
pacta (45). Another study using transgenicmice carrying 1–120
residues of human -synuclein demonstrated that this trun-
cated form rendered dopaminergic cells more susceptible to
oxidative stress (46). In our study, we failed to show the signif-
icant difference in DA neuronal death between A53T1–93 and
full-length A53T at 12 weeks of overexpression. It might be
necessary to investigate longer periods of overexpression to
observe the difference. Because A531–93 causes significant
mitochondrial toxicity, mitochondrion-focused long term in
vivo experiments might be needed.
In summary, we have shown that active MMP3-mediated
cleavage generates different pools of peptides fromWTsyn and
A53Tsyn, and it increases the propensity of protofibril-like
aggregate formations. The 1–93-amino acid peptide that is pro-
duced more abundantly from A53Tsyn elicits mitochondrial
toxicity. Overexpression of full-length andA53T1–93 in the rat
SN similarly causes degeneration of SNDA neurons, whereas
LB-like inclusions are exclusively formed by full-length
A53Tsyn. The result provides a novel insight into the -sy-
nuclein modification by activate MMP3 and its role in the
pathogenesis of PD.
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